Skip to main content
Clinical Trials/NCT04104620
NCT04104620
Unknown
Not Applicable

Autoimmunity Family Background in Neurological Syndromes With Antibodies Against Glutamic-acid Decarboxylase

Hospices Civils de Lyon0 sites100 target enrollmentSeptember 30, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Neurological Syndromes With GAD-Ab
Sponsor
Hospices Civils de Lyon
Enrollment
100
Primary Endpoint
Autoimmune organ-specific diseases in patients with GAD-Ab and their relatives
Last Updated
6 years ago

Overview

Brief Summary

A group of poorly studied immune-mediated neurological syndromes are associated with antibodies against glutamic-acid decarboxylase (GAD-Ab). GAD is the rate-limiting enzyme for the synthesis of gamma aminobutyric acid (GABA) from glutamate and is expressed by inhibitory neurons of the central nervous system. Neurological syndromes with anti-GAD antibodies (GAD-Ab) are often non-paraneoplastic. They mainly include limbic encephalitis (LE), cerebellar ataxia (CA) and stiff-person syndrome (SPS). Although the pathogenic role of GAD-Ab is controversial, most patients have high serum levels and GAD-Ab are also detected in the cerebrospinal fluid (CSF) along with other inflammatory abnormalities such as oligoclonal bands. GAD-Ab may also be present in the serum of T1DM patients, as pancreatic beta cells also express GAD, but usually at much lower titers than those of neurological patients. Organ-specific autoimmune diseases, such as T1DM and autoimmune thyroid disease, are common among patients with GAD-Ab and neurological syndromes and in their relatives, suggesting a shared genetic predisposition to autoimmune disorders. This is also supported by family reports of neurological syndromes with GAD-Ab and some HLA associations described in SPS.

The aim of this study is to describe the different autoimmune organ-specific diseases present in patients with GAD-Ab and their relatives, along with to identify families with higher aggregation of autoimmune diseases and establish potential ways of inheritability.

Detailed Description

A group of poorly studied immune-mediated neurological syndromes are associated with antibodies against glutamic-acid decarboxylase (GAD-Ab). GAD is the rate-limiting enzyme for the synthesis of gamma aminobutyric acid (GABA) from glutamate and is expressed by inhibitory neurons of the central nervous system. Neurological syndromes with anti-GAD antibodies (GAD-Ab) are often non-paraneoplastic. They mainly include limbic encephalitis (LE), cerebellar ataxia (CA) and stiff-person syndrome (SPS). Although the pathogenic role of GAD-Ab is controversial, most patients have high serum levels and GAD-Ab are also detected in the cerebrospinal fluid (CSF) along with other inflammatory abnormalities such as oligoclonal bands. GAD-Ab may also be present in the serum of T1DM patients, as pancreatic beta cells also express GAD, but usually at much lower titers than those of neurological patients. Organ-specific autoimmune diseases, such as T1DM and autoimmune thyroid disease, are common among patients with GAD-Ab and neurological syndromes and in their relatives, suggesting a shared genetic predisposition to autoimmune disorders. This is also supported by family reports of neurological syndromes with GAD-Ab and some HLA associations described in SPS. The aim of this study is to describe the different autoimmune organ-specific diseases present in patients with GAD-Ab and their relatives, along with to identify families with higher aggregation of autoimmune diseases and establish potential ways of inheritability.

Registry
clinicaltrials.gov
Start Date
September 30, 2019
End Date
September 30, 2020
Last Updated
6 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patient with a well-known neurological syndrome associated with Gad-Ab (LE, CA, SPS)
  • Patient with an CSF positive for GAD-Ab;
  • Patient witn an Age \> 18 years old.

Exclusion Criteria

  • Patient with absence of complete clinical data.
  • Patient with CSF not tested or negative for GAD-Ab

Outcomes

Primary Outcomes

Autoimmune organ-specific diseases in patients with GAD-Ab and their relatives

Time Frame: 12 Months

To collect the different autoimmune organ-specific diseases present in patients with GAD-Ab and their relatives

Secondary Outcomes

  • Inheritability in neurological syndromes with GAD-Ab(12 Months)

Similar Trials